Gene Therapy Zynteglo denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for gene therapy zynteglo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Zynteglo as Non-Formulary — and Why You Can Appeal

Blue Cross Blue Shield plans maintain tiered drug formularies, and Zynteglo (betibeglogene spartacus) — as a high-cost, one-time gene therapy — may simply not appear on your plan's formulary at all, or may require a formulary exception before coverage can be granted. A non-formulary denial does not mean the therapy is medically inappropriate; it means it has not been pre-authorized for routine coverage under your specific plan's drug list.

## Why This Denial Is Appealable

ACA §2719 and ERISA §503 guarantee your right to appeal any adverse benefit determination, including non-formulary exclusions. Most BCBS plans have a formal formulary exception process that runs parallel to or in lieu of the standard appeal. If no therapeutically equivalent formulary alternative exists — which is clearly the case for a gene therapy treating a genetic disease — the exception request is often stronger.

## Federal Appeal Framework

• Formulary exception request: File this first, simultaneously with or before the formal appeal. Demonstrate that no formulary alternative is clinically equivalent and that Zynteglo is medically necessary.
• Internal appeal (Level 1): If the exception is denied, file a formal internal appeal under ACA §2719 / ERISA §503 within the window stated on your denial letter.
• External review: Following an adverse internal decision, request IRO review under ACA §2719. The typical window is 4 months from the final adverse benefit determination — confirm the exact deadline on your denial notice.
• Expedited option: Available if delay poses serious health risk; decision required within 72 hours.

## Documentation to Gather

1. Diagnosis confirmation: Genetic and clinical records confirming transfusion-dependent beta-thalassemia. 2. No equivalent alternative argument: A prescriber letter explaining that no formulary drug achieves the same mechanism of action (gene addition) and that symptom-management alternatives are not therapeutically equivalent. 3. Prior treatment history: Records of all previously tried formulary therapies, including dates, outcomes, and why each was inadequate. 4. FDA approval documentation: Reference to Zynteglo's FDA approval for the specific indication, sourced from FDA.gov or the prescribing label. 5. Medical-necessity letter: Hematologist's detailed statement that Zynteglo is medically necessary and that no covered formulary alternative is clinically appropriate for this patient.

## Criteria-Mapping Structure

Obtain the BCBS formulary exception criteria from your plan documents or the Member Services line. Most exception processes require you to show:

| Exception Criterion | Evidence to Provide | |---|---| | No covered formulary alternative is clinically equivalent | [Prescriber letter on mechanism distinction; no gene-addition alternative exists] | | Non-formulary drug is medically necessary | [Hematologist medical-necessity letter] | | Patient meets FDA-approved indication | [Diagnosis records; FDA label indication statement] |

For the exact dose, administration requirements, and eligibility criteria, consult the FDA-approved prescribing label and the BCBS published medical/coverage policy for gene therapy. Your prescriber should document that every criterion in those sources is met in the patient's chart before you file.